Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.

Trial Details

NCT ID
NCT05866432
Phase
PHASE2
Sponsor
Medical University of Vienna
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Datopotamab deruxtecan
Locations (sample)
  • Vienna, State of Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

  • Histologically confirmed breast cancer
  • Triple-negative disease as defined by immunohistochemistry (IHC) and/or c-erb-B2 gene amplification status. For the definition of hormone-receptor …
  • Newly diagnosed untreated brain metastases or brain metastases progressing after prior local therapy
  • Measurable disease (RANO-BM criteria)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →